Processa Pharmaceuticals Inc (OQ:PCSA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 7380 Coca Cola Dr Ste 106
HANOVER MD 21076-1789
Tel: N/A
Website: https://www.processapharmaceuticals.com
IR: See website
<
Key People
George K. Ng
Chief Executive Officer, Director 		Wendy Guy
Founder, Chief Administrative Officer 		Sian Bigora
Chief Development Officer, Founder
James H. Stanker
Chief Financial Officer 		David Young
President - Research and Development, Director 		Patrick Lin
Chief Business and Strategy Officer
Business Overview
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA's) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
Financial Overview
For the fiscal year ended 31 December 2023, Processa Pharmaceuticals Inc revenues was not reported. Net loss decreased 59% to $11.1M. Lower net loss reflects Impairment of intangible asset decrease from $7.3M (expense) to $0K, General and administrative decrease of 66% to $2M (expense), Stock-based Compensation in R&D decrease of 87% to $364K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$34.05 to -$8.48.
Employees: 13 as of Mar 21, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $0.03M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$11.46M as of Dec 31, 2023
Net annual income (TTM): -$11.12M as of Dec 31, 2023
Free cash flow (TTM): -$8.06M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,855,981 as of Mar 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More